Duke W. Fu
About Duke W. Fu
Dr. Duke W. Fu, age 46, was appointed an independent director of International Isotopes Inc. on October 10, 2025 and was immediately assigned to the Audit Committee; the Board determined he meets Nasdaq independence standards . He is a Board-Certified Nuclear Pharmacist with a Doctor of Pharmacy and MBA from the University of New Mexico and postgraduate specialization at Purdue University, bringing two decades of radiopharmaceutical operations, cGMP manufacturing, and regulatory expertise . His initial director compensation is equity-based via RSUs and expense reimbursement under a Board Appointment and Compensation Agreement dated October 10, 2025 .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Green Therapeutics | Chief Executive Officer | Since 2015 | Led operational excellence and market expansion in healthcare distribution and nuclear pharmacy contexts |
| Australis Capital | Interim CEO and Chief Operating Officer | 2020–2022 | Public-company operating leadership; scaled operations and compliance |
| Biotech Pharmacy (acquired by Cardinal Health in 2009) | Managing Partner | Pre-2009 | Oversaw nuclear pharmaceutical manufacturing and commercial development of imaging/therapeutic agents |
| Cardinal Health | Manager (post-acquisition) | Post-2009 | Continued leadership in nuclear pharmaceutical operations |
External Roles
| Category | Details |
|---|---|
| Current public company boards | Not specified in INIS 8-K appointment biography |
| Prior public company boards | Not specified; 8-K notes “public board directorship” experience generically without naming entities |
| Non-profit/academic boards | Not disclosed |
Board Governance
- Independence: Board determined Dr. Fu is independent under Nasdaq standards and appointed him to the Audit Committee .
- Committees:
- Audit Committee: Member (appointed October 10, 2025). The Audit Committee oversees financial statements, auditor independence, and compliance processes .
- Nominating & Corporate Governance Committee: Company created this committee in Q3 2025; no disclosure that Dr. Fu is a member or chair .
- Attendance: Appointed in October 2025; no attendance data yet for Dr. Fu. For context, all directors in 2024 met at least 75% attendance, but Dr. Fu was not yet on the Board .
- Policies: Code of Ethics in place; anti-hedging and anti-pledging are discouraged (no formal hedging/pledging policy) .
- Board leadership: Independent Chair separate from CEO; Audit Committee chaired by Christopher Grosso as of 2025 proxy (pre-dating Dr. Fu’s appointment) .
Fixed Compensation (Director)
| Component | Amount/Terms | Source |
|---|---|---|
| Annual cash retainer | None disclosed for non-employee directors generally; company “generally does not pay” retainers or other fees | |
| Meeting fees | None disclosed | |
| Committee membership fees | None disclosed | |
| Committee chair fees | None disclosed | |
| Expense reimbursement | Reimburses actual out-of-pocket expenses for Board participation (applies to Dr. Fu per agreement) |
Performance Compensation (Director)
| Equity Type | Grant/Term | Vesting/Conditions | Notes |
|---|---|---|---|
| RSUs | 250,000 RSUs per annual term served under Board Appointment and Compensation Agreement dated Oct 10, 2025 | Vesting commencement date for initial 250,000 RSUs is July 11, 2026; annual term runs until next annual meeting (not to exceed one year) | No performance metrics disclosed; time-based vesting |
Other Directorships & Interlocks
| Type | Entity | Role | Overlap/Interlock |
|---|---|---|---|
| Public company board(s) | Not specified in INIS filings for Dr. Fu | — | — |
| Private company leadership | Green Therapeutics | CEO | None disclosed with INIS customers/suppliers |
| Prior roles with potential interlocks | Australis Capital (public) 2020–2022; Cardinal Health (post-2009) | Interim CEO/COO; Manager | No INIS related-party ties disclosed for Dr. Fu |
Expertise & Qualifications
- Board-Certified Nuclear Pharmacist; cGMP production and radiopharmaceutical manufacturing expertise .
- PharmD and MBA (University of New Mexico); postdoctoral specialization at Purdue University .
- Senior operating leadership across nuclear pharmacy and healthcare distribution; regulatory compliance and market expansion experience .
Equity Ownership
| Item | Status |
|---|---|
| Beneficial ownership at May 19, 2025 | Not listed in the beneficial ownership table (appointment occurred Oct 10, 2025, after the May 19, 2025 record date) |
| Initial director equity | 250,000 RSUs for the initial annual term (vesting commencement July 11, 2026) |
| Vested vs unvested | Unvested as of appointment; vesting commencement set for July 11, 2026 |
| Shares pledged as collateral | None disclosed for Dr. Fu; company discourages pledging |
Governance Assessment
- Positives:
- Independent appointment and immediate assignment to Audit Committee strengthen financial oversight and industry-specific risk monitoring .
- Deep radiopharmaceutical and GMP manufacturing background aligns with INIS’s operational and regulatory risk profile .
- Director pay structure is equity-centric (RSUs) with no fixed cash retainer, reinforcing alignment with shareholders .
- No related-party transactions or arrangements for Dr. Fu requiring Item 404(a) disclosure; clean conflicts profile at appointment .
- Watch items:
- New Nominating & Corporate Governance Committee created in Q3 2025—committee composition and independence posture post-creation not yet disclosed; monitor assignments and charters for effectiveness .
- Broader governance environment includes concentrated ownership and legacy related-party financing (historical notes to prior executives); while not tied to Dr. Fu, committee vigilance on conflicts is warranted .
- Anti-hedging/pledging is “discouraged” rather than formally prohibited; Audit and Governance Committees may consider codifying stricter policies for director alignment .
No adverse attendance, legal proceedings, or related-party issues specific to Dr. Fu were disclosed as of his appointment date .